Human CD47 Knockout Cell Line-K562
Cat.No. : CSC-RT2758
Host Cell: K562 Target Gene: CD47
Size: 1x10^6 cells/vial, 1mL Validation: Sequencing
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
| Cat. No. | CSC-RT2758 |
| Cell Line Information | This cell is a stable cell line with a homozygous knockout of human CD47 using CRISPR/Cas9. |
| Target Gene | CD47 |
| Host Cell | K562 |
| Size Form | 1 vial (>10^6 cell/vial) |
| Shipping | Dry ice package |
| Storage | Liquid Nitrogen |
| Species | Human |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Background
Applications
CD47, also known as integrin-associated protein (IAP), is a transmembrane protein widely expressed on various cell types in the human body. It plays a crucial role in a range of cellular processes, including apoptosis, proliferation, adhesion, and migration. CD47 primarily interacts with its receptor, signal regulatory protein α (SIRPα), which is primarily found on macrophages and dendritic cells. This interaction is a key "don't eat me" signal to the immune system, preventing macrophages from engulfing healthy cells.
Many tumor cells overexpress CD47, thereby exploiting the "don't eat me" signal to evade clearance by the immune system. This overexpression is often associated with a poor prognosis in various cancers because it allows malignant cells to proliferate and metastasize without being inhibited by the body's natural defenses. Therefore, CD47 has attracted great interest as a therapeutic target for cancer treatment. Monoclonal antibodies designed to block the interaction between CD47 and SIRPα are currently being studied in clinical trials, with the potential to enhance the body's ability to fight cancer by promoting phagocytosis of tumor cells.
1. Cancer Research: CD47 is known as the "don't eat me" signal that cancer cells use to evade immune surveillance. By knocking out CD47, researchers can study how the loss of this protein affects tumor cell behavior and immune system interactions, thereby exploring new therapeutic strategies to enhance anti-tumor immunity.
2. Immunotherapy Development: CD47 knockout K562 cells play an important role in the development and testing of immunotherapies. These cells can be used to screen drugs and antibodies that target the CD47-SIRPα interaction.
3. Hematopoietic Stem Cell Research: K562 is a leukemic cell line derived from a patient with chronic myeloid leukemia. Studying CD47-deficient K562 cells helps to gain insight into the role of CD47 in hematopoietic stem cell biology and leukemia development.
4. Drug Resistance Research: Analysis of drug resistance mechanisms in CD47 knockout K562 cells can reveal how CD47 leads to resistance to various chemotherapeutic drugs. By understanding these mechanisms, researchers can develop strategies to overcome drug resistance in cancer treatment, thereby improving treatment outcomes and patient survival.
5. Cell Signaling Pathway Studies: The K562 CD47 knockout cell line is also used to dissect cell signaling pathways involved in immune evasion and cellular homeostasis. By comparing signaling pathways in wild-type and CD47 knockout cells, scientists can identify key molecules and interactions affected by the loss of CD47.
For research use only. Not intended for any clinical use.
